Advancing Base Metal Catalysis in Pharma
- Type: Archived Webinar
- Level: Intermediate
- Duration: 1 hour
- PDHs: 1.00
Involved in metal catalysis in the pharmaceutical industry? Relying on precious metal catalysts? This webinar is for you.
In 60 minutes, this webinar will discuss the pros and cons of base metal catalysts and precious metal catalysts from a cost, toxicity and supply risk perspective. You’ll consider the application of copper, iron and nickel base metal catalysts to metal-catalyzed cross-coupling reactions. You’ll learn the benefits and limitations when compared to the most common cross-coupling metal catalyst, palladium. Through examples and specific Pfizer case studies, you’ll understand the advantages base metals offer and you’ll be able to identify opportunities where base metal catalysts can be applied.
Take a look at your agenda:
- The impact of palladium catalyzed cross-coupling on the pharmaceutical industry
- Iron, copper and nickel compared to palladium
- Recent chemical transformations catalyzed by base metals that are not amenable to palladium catalysts
- Identifying opportunities to apply base metal catalysts
J. Christopher McWilliams
Chris McWilliams is currently a Director of Process Chemistry within the Chemical Research and Development organization at Pfizer. Chris received his Ph.D. in organic chemistry after completing the total synthesis of (+)-Octalactin A at Cornell University in 1994, and following post-doctoral research in the field of asymmetric synthetic methodology in Professor Gary Molander’s lab, he began a career in the pharmaceutical industry in 1995.
Over the last 21 years, Chris has enjoyed many roles as a lab scientist and manager that span process development and scale up, catalysis,...Read more
|AIChE Member Credits||1|
|AIChE Graduate Student Members||Free|
|AIChE Undergraduate Student Members||Free|